Market Summary
USD329.99-2.64
Market Closed-0.79%
VRTX Alerts
VRTX Stock Price
VRTX RSI Chart
VRTX Valuation
VRTX Price/Sales (Trailing)
VRTX Profitability
VRTX Fundamentals
VRTX Revenue
VRTX Earnings
Price Action
52 Week Range
243.17354.46
(Low)(High)
Last 7 days
-3.4%
Last 30 days
2.1%
Last 90 days
14.8%
Trailing 12 Months
22.4%
VRTX Financial Health
VRTX Investor Care
Peers (Alternatives to Vertex Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
BGNE | 322.8B | 1.6B | -3.71% | 80.48% | -168.39 | 207.32 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -14.98% | -6.85% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -6.81% | 6.09% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 85.0B | 9.2B | 2.07% | 22.38% | 26.07 | 9.23 | 15.86% | 32.99% |
ALNY | 23.4B | 1.0B | -4.69% | 49.89% | -21.96 | 22.55 | 22.88% | -19.27% |
SRPT | 11.8B | 975.7M | 3.71% | 78.87% | -10.59 | 12.11 | 27.41% | -212.78% |
UTHR | 9.7B | 2.0B | -8.21% | -7.77% | 13.31 | 4.89 | 12.05% | 52.86% |
| MID-CAP | ||||||||
MDGL | 5.2B | 504.0K | -7.29% | 316.43% | -16.55 | 2.5K | -66.53% | -27.52% |
RARE | 3.5B | 363.3M | 17.72% | 8.70% | -4.94 | 9.63 | 3.39% | -55.81% |
BPMC | 3.5B | 204.6M | 17.81% | 4.32% | -6 | 17.05 | -7.52% | 10.65% |
MRTX | 2.2B | 18.9M | -10.74% | -34.21% | -3.03 | 118.36 | - | -16.17% |
| SMALL-CAP | ||||||||
CYTK | 3.5B | - | 0.59% | -4.18% | -8.22 | 37.46 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -28.21% | 63.82% | 12.26 | 4.75 | 66.85% | 120.61% |
MGNX | 315.4M | 165.3M | -25.22% | 48.69% | -3.45 | 1.91 | 130.70% | 57.97% |
CRBP | 41.8M | 881.7K | 29.00% | 3203.36% | -0.83 | 19.11 | -77.61% | -29.84% |
Financials for Vertex Pharmaceuticals
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 3.1% | 9,208 | 8,931 | 8,701 | 8,350 | 7,948 |
| S&GA Expenses | 2.7% | 971 | 945 | 933 | 884 | 863 |
| R&D Expenses | - | 3,198 | - | - | - | - |
| Costs and Expenses | 11.7% | 5,163 | 4,623 | 4,549 | 4,271 | 5,012 |
| EBITDA | 5.2% | 4,326 | 4,112 | 4,012 | 2,936 | - |
| EBITDA Margin | 2.5% | 0.48* | 0.47* | 0.48* | 0.37* | - |
| Earnings Before Taxes | -1.5% | 4,169 | 4,232 | 4,027 | 3,933 | 2,864 |
| EBT Margin | 2.4% | 0.47* | 0.46* | 0.47* | 0.36* | - |
| Interest Expenses | 6.0% | -54.80 | -58.30 | -59.80 | -60.70 | - |
| Net Income | -1.9% | 3,260 | 3,322 | 3,273 | 3,195 | 2,451 |
| Net Income Margin | -1.1% | 0.37* | 0.38* | 0.38* | 0.31* | - |
| Free Cahsflow | 2.9% | 3,925 | 3,814 | 3,787 | 2,451 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | 4.5% | 18,974 | 18,151 | 16,706 | 15,582 | 14,256 |
| Current Assets | -2.0% | 12,966 | 13,235 | 12,271 | 11,504 | 10,361 |
| Cash Equivalents | -11.6% | 9,290 | 10,504 | 9,172 | 8,702 | 7,600 |
| Inventory | 16.2% | 535 | 461 | 388 | 368 | 339 |
| Goodwill | -1.1% | 1,088 | 1,100 | 86.00 | 1,002 | 1,002 |
| Liabilities | 7.2% | 4,542 | 4,238 | 3,677 | 3,649 | 3,349 |
| Current Liabilities | 10.4% | 3,026 | 2,742 | 2,609 | 2,556 | 2,180 |
| Shareholder's Equity | 3.7% | 14,432 | 13,913 | 13,030 | 11,934 | 10,907 |
| Retained Earnings | 10.7% | 7,223 | 6,523 | 5,704 | 4,773 | 3,963 |
| Additional Paid-In Capital | -2.3% | 7,220 | 7,387 | 7,226 | 7,100 | 6,930 |
| Shares Outstanding | 0.2% | 258 | 257 | 257 | 256 | 256 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | -1.4% | 4,074 | 4,130 | 4,047 | 4,018 | 2,679 |
| Share Based Compensation | -1.6% | 483 | 491 | 498 | 466 | 457 |
| Cashflow From Investing | -555.2% | -2,103 | -321 | -630 | -299 | -317 |
| Cashflow From Financing | -294.4% | -267 | -67.70 | -444 | -1,040 | -1,054 |
| Buy Backs | Infinity% | 133 | 0.00 | 368 | 1,010 | 1,010 |
Risks for VRTX
What is the probability of a big loss on VRTX?
25.8%
Probability that Vertex Pharmaceuticals stock will be more than 20% underwater in next one year
6.5%
Probability that Vertex Pharmaceuticals stock will be more than 30% underwater in next one year.
0%
Probability that Vertex Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does VRTX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Vertex Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Returns for VRTX
Cumulative Returns on VRTX
15.5%
10-Year Cumulative Returns
20.3%
7-Year Cumulative Returns
15.9%
5-Year Cumulative Returns
7.4%
3-Year Cumulative Returns
What are the long-term rolling returns for VRTX?
FIve years rolling returns for Vertex Pharmaceuticals.
Annualized Returns
Which funds bought or sold VRTX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-24 | Old North State Trust, LLC | unchanged | - | 3,000 | 32,000 | 0.02% |
2023-05-23 | Toroso Investments, LLC | added | 43.09 | 3,909,000 | 10,878,000 | 0.19% |
2023-05-23 | Seaport Global Advisors, LLC | reduced | -34.06 | -138,205 | 354,454 | 1.12% |
2023-05-23 | Brookfield Corp /ON/ | new | - | 366,426 | 366,426 | -% |
2023-05-23 | 3Chopt Investment Partners, LLC | new | - | 1,920,350 | 1,920,350 | 1.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -5.28 | 34,587,100 | 1,068,030,000 | 0.35% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -11.22 | -1,213,060 | 37,475,400 | 0.06% |
2023-05-22 | Raleigh Capital Management Inc. | new | - | 5,986 | 5,986 | -% |
2023-05-22 | Arete Wealth Advisors, LLC | new | - | 236,000 | 236,000 | 0.02% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 2,075,000 | 0.09% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
VRTX Alerts
Vertex Pharmaceuticals News
Schedule 13G FIlings of Vertex Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital world investors | 5.0% | 12,939,319 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 8.39% | 21,546,903 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G | |
| Jan 24, 2023 | blackrock inc. | 9.4% | 24,241,437 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 2.1% | 5,421,291 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 7.93% | 20,155,842 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 9.4% | 23,944,931 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 7.5% | 19,626,208 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.86% | 20,433,050 | SC 13G/A |
VRTX Fair Value
Recent SEC filings of Vertex Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 18, 2023 | 8-K | Current Report | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading | |
| May 08, 2023 | 144 | Notice of Insider Sale Intent | |
| May 08, 2023 | 144 | Notice of Insider Sale Intent | |
| May 05, 2023 | 144 | Notice of Insider Sale Intent | |
| May 05, 2023 | 144 | Notice of Insider Sale Intent | |
| May 04, 2023 | 4 | Insider Trading | |
| May 04, 2023 | 4 | Insider Trading | |
| May 03, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for VRTX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-08 | Sanna Bastiano | sold | -997,500 | 350 | -2,850 | evp, cell & genetic therapies |
2023-05-08 | LEIDEN JEFFREY M | sold | -392,625 | 349 | -1,125 | executive chairman |
2023-05-05 | LEIDEN JEFFREY M | sold | -307,262 | 349 | -879 | executive chairman |
2023-05-05 | Sanna Bastiano | sold | -147,713 | 350 | -422 | evp, cell & genetic therapies |
2023-05-03 | Sanna Bastiano | sold | -975,418 | 350 | -2,781 | evp, cell & genetic therapies |
2023-05-03 | LEIDEN JEFFREY M | sold | -1,578,300 | 350 | -4,508 | executive chairman |
2023-05-02 | Sanna Bastiano | sold | -568,768 | 350 | -1,622 | evp, cell & genetic therapies |
2023-05-02 | Bhatia Sangeeta N. | sold | -202,004 | 348 | -580 | - |
2023-05-02 | LEIDEN JEFFREY M | sold | -2,256,760 | 349 | -6,450 | executive chairman |
2023-05-01 | MCKENZIE DIANA | acquired | - | - | 1,168 | - |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX Income Statement
2023-03-31Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Revenues: | ||
| Product revenues, net | $ 2,374.8 | $ 2,097.5 |
| Costs and expenses: | ||
| Cost of sales | 266.9 | 245.8 |
| Research and development expenses | 742.6 | 601.1 |
| Acquired in-process research and development expenses | 347.1 | 2.0 |
| Selling, general and administrative expenses | 241.1 | 215.2 |
| Change in fair value of contingent consideration | (1.9) | (7.5) |
| Total costs and expenses | 1,595.8 | 1,056.6 |
| Income from operations | 779.0 | 1,040.9 |
| Interest income | 122.6 | 1.6 |
| Interest expense | (11.4) | (14.9) |
| Other income (expense), net | 1.3 | (72.8) |
| Income before provision for income taxes | 891.5 | 954.8 |
| Provision for income taxes | 191.7 | 192.7 |
| Net income | $ 699.8 | $ 762.1 |
| Net income per common share: | ||
| Basic (in dollars per share) | $ 2.72 | $ 2.99 |
| Diluted (in dollars per share) | $ 2.69 | $ 2.96 |
| Shares used in per share calculations: | ||
| Basic (in shares) | 257.4 | 255.1 |
| Diluted (in shares) | 260.3 | 257.9 |
VRTX Balance Sheet
2023-03-31Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 9,289.9 | $ 10,504.0 |
| Marketable securities | 1,124.2 | 274.5 |
| Accounts receivable, net | 1,547.8 | 1,442.2 |
| Inventories | 535.1 | 460.6 |
| Prepaid expenses and other current assets | 468.7 | 553.5 |
| Total current assets | 12,965.7 | 13,234.8 |
| Property and equipment, net | 1,111.7 | 1,108.4 |
| Goodwill | 1,088.0 | 1,088.0 |
| Intangible assets | 603.6 | 603.6 |
| Deferred tax assets | 1,359.9 | 1,246.9 |
| Operating lease assets | 336.3 | 347.4 |
| Long-term marketable securities | 1,081.5 | 112.2 |
| Other assets | 427.5 | 409.6 |
| Total assets | 18,974.2 | 18,150.9 |
| Current liabilities: | ||
| Accounts payable | 323.2 | 303.9 |
| Accrued expenses | 2,326.0 | 2,126.7 |
| Other current liabilities | 377.0 | 311.5 |
| Total current liabilities | 3,026.2 | 2,742.1 |
| Long-term finance lease liabilities | 417.6 | 430.8 |
| Long-term operating lease liabilities | 371.6 | 379.5 |
| Other long-term liabilities | 726.5 | 685.8 |
| Total liabilities | 4,541.9 | 4,238.2 |
| Commitments and contingencies | 0.0 | 0.0 |
| Shareholders’ equity: | ||
| Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding | 0.0 | 0.0 |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively | 2.6 | 2.6 |
| Additional paid-in capital | 7,220.2 | 7,386.5 |
| Accumulated other comprehensive (loss) income | (13.1) | 0.8 |
| Retained earnings | 7,222.6 | 6,522.8 |
| Total shareholders’ equity | 14,432.3 | 13,912.7 |
| Total liabilities and shareholders’ equity | $ 18,974.2 | $ 18,150.9 |